<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04280315</url>
  </required_header>
  <id_info>
    <org_study_id>SkinBarrier_30092019</org_study_id>
    <nct_id>NCT04280315</nct_id>
  </id_info>
  <brief_title>Investigation of the Skin Barrier in Patients With Type 1 Diabetes</brief_title>
  <official_title>Investigation of the Skin Barrier in Patients With Type 1 Diabetes - a Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jannet Svensson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a case-control study comparing the skin barrier between 50 T1D patients with&#xD;
      healthy controls in 3 age-strata including both pediatric and adult patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The skin is a crucial barrier against external allergens and irritants. Therefore the&#xD;
      function of the skin barrier is central regarding evolvement of eczema. In patients with type&#xD;
      1 diabetes (T1D) using insulin pumps and/or glucose sensor, eczema is unfortunately a&#xD;
      frequent reaction. The skin consists of three layers: epidermis, dermis and subcutaneous fat,&#xD;
      whereas epidermis is most determining regarding skin barrier. Epidermis can further be&#xD;
      subdivided, where stratum corneum (SC) is the outer part, which means most regarding&#xD;
      vulnerability towards external allergens.&#xD;
&#xD;
      The function of the skin barrier can be investigated by non-invasive methods using&#xD;
      transepidermal water loss (TEWL), which shows the water vapour flux from the skin. Besides SC&#xD;
      can be determined using the tape strip method, where few SC cells are peeled off and thereby&#xD;
      can be analyzed with mass-spectrometry. Natural moisturizing factors (NMF) is though one of&#xD;
      the very important functionalities of the SC, which are determined by the amount of&#xD;
      2-pyrrolidone-5-carboxylic acid (PCA). Besides, the lipid distribution, presence of&#xD;
      antimicrobial peptide and cytokine response give as well important information regarding the&#xD;
      skin barrier.&#xD;
&#xD;
      Dermatological manifestations of T1D are quite frequent and have been shown to be related to&#xD;
      glycemic control, placing dermatological manifestations as a precursor of other microvascular&#xD;
      complications11. There is a lack of studies regarding skin barrier function in patients with&#xD;
      T1D, and especially in a pediatric study population. Therefore, this case-control study will&#xD;
      be conducted investigating skin barrier function in pediatric patients with T1D compared to&#xD;
      healthy controls in order to both meet this lack of knowledge, but as well to improve the&#xD;
      prevention of skin problems to devices used in T1D-treatment.&#xD;
&#xD;
      The examination program of just one visit per participant consists of:&#xD;
&#xD;
        -  TEWL-measure at forearm and buttock&#xD;
&#xD;
        -  Buccal swab regarding filaggrin gene status&#xD;
&#xD;
        -  Microbiological swab from the skin at forearm and buttock&#xD;
&#xD;
        -  2X11 tape strips from the skin at foream and buttock to be analyzed for NMF, Lipid,&#xD;
           Cytokines, Antimicrobial peptide and Dermal Topographical Index as well as protein&#xD;
           content using SquameScan&#xD;
&#xD;
        -  Measure of skin PH, hydration and sebum content at forearm and buttock&#xD;
&#xD;
        -  Capillary Blood Glucose&#xD;
&#xD;
        -  Survey regarding atopic and dermatological symptoms&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>TEWL</measure>
    <time_frame>Baseline</time_frame>
    <description>Transepidermal Water Loss measured by an Aquaflux AF1000</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin barrier properties described with Tape Strips</measure>
    <time_frame>Baseline</time_frame>
    <description>Tape strips will be analyzed according to Natural Moisturizing Factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Filaggrin mutation Status</measure>
    <time_frame>Baseline</time_frame>
    <description>Filaggrin DNA status regarding common SNPs in DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin pH</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured with DermaUnit SSC3 Skin pH-Meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin hydration</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured with DermaUnit SSC3 Corneometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sebum content in skin</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured with DermaUnit SSC3 Sebumeter</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Cases are patients with type 1 diabetes in three age strata:&#xD;
20 participants in the age of 2-10 years&#xD;
20 participants in the age of 11-20 years&#xD;
10 participants with more than 30 years of diabetes duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Controls are age and sexmatched with the cases and are recruited from the neuropediatric clinic at Herlev Hospital as well as relatives and parents of patients in the whole Pediatric Department</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Buccal Swab for DNA extraction&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study Population are included from the Pediatric department in the diabetes group for&#xD;
        patients and primarily in the neurogroup for controls. Adult cases are included from Steno&#xD;
        Diabetes Center Copenhagen and adult controls as parents to patients included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cases:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with type 1 diabetes, more than 6 months ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Skin lesions at both buttocks and forearms so investigation can not be done&#xD;
&#xD;
          -  Known skin diseases with decreased barrier function like atopic dermatitis, psoriasis&#xD;
             and allergic contact dermatitis&#xD;
&#xD;
          -  Active infectious disease&#xD;
&#xD;
          -  Use of immunosuppressive medication e.g. steroids&#xD;
&#xD;
          -  Lack of language competence in Danish&#xD;
&#xD;
        Controls:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with Tourettes or Headache OR sibling for patients in the 1813-clinic at&#xD;
             Pediatric Emergency Toom OR Hospitalized patients at Pediatric department OR Parents&#xD;
             to alle these&#xD;
&#xD;
        Exclusion Criteria are equal to exclusion criteria in cases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Korsgaard Berg, MD</last_name>
    <phone>38681089</phone>
    <phone_ext>+45</phone_ext>
    <email>anna.korsgaard.berg.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jannet Svensson, MD, PhD</last_name>
    <phone>38681089</phone>
    <phone_ext>+45</phone_ext>
    <email>jannet.svensson@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <state>Region Hovedstaden</state>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten NÃ¸rgaard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <state>Region Hovedstaden</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Korsgaard Berg, MD</last_name>
      <email>anna.korsgaard.berg.02@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>https://www.herlevhospital.dk/afdelinger-og-klinikker/Afdeling-for-Boern-og-Unge/Forskningsprojekter/Sider/Diabetes/Hudproblemer-i-forbindelse-med-insulinpumpe-og-sensor.aspx</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Jannet Svensson</investigator_full_name>
    <investigator_title>MD, PhD, Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Dermatology</keyword>
  <keyword>Skin Barrier Function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

